nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—myometrium—ovarian cancer	0.0473	0.116	CbGeAlD
Plerixafor—CXCR4—embryo—ovarian cancer	0.0455	0.112	CbGeAlD
Plerixafor—CXCR4—epithelium—ovarian cancer	0.0371	0.091	CbGeAlD
Plerixafor—CXCR4—uterine cervix—ovarian cancer	0.0368	0.0903	CbGeAlD
Plerixafor—CXCR4—decidua—ovarian cancer	0.0351	0.086	CbGeAlD
Plerixafor—CXCR4—endometrium—ovarian cancer	0.0333	0.0816	CbGeAlD
Plerixafor—CXCR4—uterus—ovarian cancer	0.0307	0.0752	CbGeAlD
Plerixafor—CXCR4—female reproductive system—ovarian cancer	0.0276	0.0676	CbGeAlD
Plerixafor—CXCR4—bone marrow—ovarian cancer	0.026	0.0638	CbGeAlD
Plerixafor—CXCR4—female gonad—ovarian cancer	0.0251	0.0615	CbGeAlD
Plerixafor—CXCR4—vagina—ovarian cancer	0.0249	0.0612	CbGeAlD
Plerixafor—CXCR4—testis—ovarian cancer	0.0222	0.0546	CbGeAlD
Plerixafor—CXCR4—lymph node—ovarian cancer	0.0161	0.0396	CbGeAlD
Plerixafor—CXCR4—HIV Life Cycle—CHMP4C—ovarian cancer	0.00876	0.0891	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—CHMP4C—ovarian cancer	0.00605	0.0615	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—SLC2A1—ovarian cancer	0.00523	0.0532	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—ABCB1—ovarian cancer	0.00413	0.042	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—VEGFA—ovarian cancer	0.00387	0.0393	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—MAPK3—ovarian cancer	0.00366	0.0372	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—MMP9—ovarian cancer	0.00354	0.036	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—TERT—ovarian cancer	0.00353	0.0359	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—MAPK1—ovarian cancer	0.00348	0.0354	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CXCL8—ovarian cancer	0.0025	0.0254	CbGpPWpGaD
Plerixafor—CXCR4—S1P3 pathway—AKT1—ovarian cancer	0.00247	0.0251	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CG—ovarian cancer	0.00245	0.0249	CbGpPWpGaD
Plerixafor—Feeling abnormal—Chlorambucil—ovarian cancer	0.0023	0.00465	CcSEcCtD
Plerixafor—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.00228	0.00461	CcSEcCtD
Plerixafor—Injection site reaction—Epirubicin—ovarian cancer	0.00227	0.0046	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.00226	0.00458	CcSEcCtD
Plerixafor—Orthostatic hypotension—Docetaxel—ovarian cancer	0.00225	0.00455	CcSEcCtD
Plerixafor—Paraesthesia—Topotecan—ovarian cancer	0.00223	0.00451	CcSEcCtD
Plerixafor—Urticaria—Chlorambucil—ovarian cancer	0.00221	0.00448	CcSEcCtD
Plerixafor—Arthralgia—Vinorelbine—ovarian cancer	0.00221	0.00448	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.00221	0.00448	CcSEcCtD
Plerixafor—Dyspnoea—Topotecan—ovarian cancer	0.00221	0.00448	CcSEcCtD
Plerixafor—Abdominal pain—Chlorambucil—ovarian cancer	0.0022	0.00446	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—ovarian cancer	0.0022	0.00445	CcSEcCtD
Plerixafor—Discomfort—Vinorelbine—ovarian cancer	0.00219	0.00443	CcSEcCtD
Plerixafor—Dyspepsia—Topotecan—ovarian cancer	0.00218	0.00442	CcSEcCtD
Plerixafor—Inflammation—Doxorubicin—ovarian cancer	0.00218	0.00442	CcSEcCtD
Plerixafor—Paraesthesia—Melphalan—ovarian cancer	0.00218	0.00442	CcSEcCtD
Plerixafor—Dyspnoea—Melphalan—ovarian cancer	0.00217	0.00439	CcSEcCtD
Plerixafor—Musculoskeletal pain—Doxorubicin—ovarian cancer	0.00214	0.00434	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00214	0.00434	CcSEcCtD
Plerixafor—Fatigue—Topotecan—ovarian cancer	0.00214	0.00433	CcSEcCtD
Plerixafor—Dyspepsia—Melphalan—ovarian cancer	0.00214	0.00433	CcSEcCtD
Plerixafor—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00212	0.0043	CcSEcCtD
Plerixafor—Pain—Topotecan—ovarian cancer	0.00212	0.0043	CcSEcCtD
Plerixafor—Constipation—Topotecan—ovarian cancer	0.00212	0.0043	CcSEcCtD
Plerixafor—Injection site reaction—Doxorubicin—ovarian cancer	0.0021	0.00426	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Melphalan—ovarian cancer	0.0021	0.00425	CcSEcCtD
Plerixafor—Fatigue—Melphalan—ovarian cancer	0.00209	0.00424	CcSEcCtD
Plerixafor—Nervous system disorder—Vinorelbine—ovarian cancer	0.00208	0.00421	CcSEcCtD
Plerixafor—Pain—Melphalan—ovarian cancer	0.00208	0.00421	CcSEcCtD
Plerixafor—Skin disorder—Vinorelbine—ovarian cancer	0.00206	0.00417	CcSEcCtD
Plerixafor—Hypersensitivity—Chlorambucil—ovarian cancer	0.00205	0.00416	CcSEcCtD
Plerixafor—Feeling abnormal—Topotecan—ovarian cancer	0.00205	0.00414	CcSEcCtD
Plerixafor—Gastrointestinal pain—Topotecan—ovarian cancer	0.00203	0.00411	CcSEcCtD
Plerixafor—Haemoglobin—Paclitaxel—ovarian cancer	0.00202	0.00409	CcSEcCtD
Plerixafor—Haemorrhage—Paclitaxel—ovarian cancer	0.00201	0.00407	CcSEcCtD
Plerixafor—Asthenia—Chlorambucil—ovarian cancer	0.002	0.00405	CcSEcCtD
Plerixafor—Connective tissue disorder—Paclitaxel—ovarian cancer	0.00198	0.004	CcSEcCtD
Plerixafor—Pruritus—Chlorambucil—ovarian cancer	0.00197	0.00399	CcSEcCtD
Plerixafor—Urticaria—Topotecan—ovarian cancer	0.00197	0.00399	CcSEcCtD
Plerixafor—Abdominal pain—Topotecan—ovarian cancer	0.00196	0.00397	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.00193	0.00392	CcSEcCtD
Plerixafor—Urticaria—Melphalan—ovarian cancer	0.00193	0.00391	CcSEcCtD
Plerixafor—Diarrhoea—Chlorambucil—ovarian cancer	0.00191	0.00386	CcSEcCtD
Plerixafor—Paraesthesia—Vinorelbine—ovarian cancer	0.00191	0.00386	CcSEcCtD
Plerixafor—Dyspnoea—Vinorelbine—ovarian cancer	0.00189	0.00383	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MTOR—ovarian cancer	0.00188	0.0191	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CB—ovarian cancer	0.00188	0.0191	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HSD17B6—ovarian cancer	0.00185	0.0189	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL6—ovarian cancer	0.00184	0.0187	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00183	0.00371	CcSEcCtD
Plerixafor—Fatigue—Vinorelbine—ovarian cancer	0.00183	0.00371	CcSEcCtD
Plerixafor—Hypersensitivity—Topotecan—ovarian cancer	0.00183	0.0037	CcSEcCtD
Plerixafor—Constipation—Vinorelbine—ovarian cancer	0.00182	0.00367	CcSEcCtD
Plerixafor—Pain—Vinorelbine—ovarian cancer	0.00182	0.00367	CcSEcCtD
Plerixafor—Immune system disorder—Paclitaxel—ovarian cancer	0.00182	0.00367	CcSEcCtD
Plerixafor—Hypersensitivity—Melphalan—ovarian cancer	0.00179	0.00362	CcSEcCtD
Plerixafor—Asthenia—Topotecan—ovarian cancer	0.00178	0.0036	CcSEcCtD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—VEGFA—ovarian cancer	0.00178	0.0181	CbGpPWpGaD
Plerixafor—Vomiting—Chlorambucil—ovarian cancer	0.00177	0.00359	CcSEcCtD
Plerixafor—Mental disorder—Paclitaxel—ovarian cancer	0.00176	0.00356	CcSEcCtD
Plerixafor—Pruritus—Topotecan—ovarian cancer	0.00176	0.00355	CcSEcCtD
Plerixafor—Erythema—Paclitaxel—ovarian cancer	0.00175	0.00354	CcSEcCtD
Plerixafor—Feeling abnormal—Vinorelbine—ovarian cancer	0.00175	0.00354	CcSEcCtD
Plerixafor—Asthenia—Melphalan—ovarian cancer	0.00174	0.00353	CcSEcCtD
Plerixafor—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.00174	0.00351	CcSEcCtD
Plerixafor—Flatulence—Paclitaxel—ovarian cancer	0.00172	0.00349	CcSEcCtD
Plerixafor—Pruritus—Melphalan—ovarian cancer	0.00172	0.00348	CcSEcCtD
Plerixafor—Haemoglobin—Docetaxel—ovarian cancer	0.00171	0.00347	CcSEcCtD
Plerixafor—Haemorrhage—Docetaxel—ovarian cancer	0.0017	0.00345	CcSEcCtD
Plerixafor—Diarrhoea—Topotecan—ovarian cancer	0.0017	0.00344	CcSEcCtD
Plerixafor—Urticaria—Vinorelbine—ovarian cancer	0.00169	0.00341	CcSEcCtD
Plerixafor—Abdominal pain—Vinorelbine—ovarian cancer	0.00168	0.0034	CcSEcCtD
Plerixafor—Connective tissue disorder—Docetaxel—ovarian cancer	0.00167	0.00339	CcSEcCtD
Plerixafor—Diarrhoea—Melphalan—ovarian cancer	0.00166	0.00337	CcSEcCtD
Plerixafor—Nausea—Chlorambucil—ovarian cancer	0.00166	0.00335	CcSEcCtD
Plerixafor—Dizziness—Topotecan—ovarian cancer	0.00164	0.00332	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MMP9—ovarian cancer	0.00163	0.0166	CbGpPWpGaD
Plerixafor—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00162	0.00329	CcSEcCtD
Plerixafor—Vomiting—Topotecan—ovarian cancer	0.00158	0.00319	CcSEcCtD
Plerixafor—Malaise—Paclitaxel—ovarian cancer	0.00158	0.00319	CcSEcCtD
Plerixafor—Syncope—Paclitaxel—ovarian cancer	0.00157	0.00318	CcSEcCtD
Plerixafor—Rash—Topotecan—ovarian cancer	0.00156	0.00317	CcSEcCtD
Plerixafor—Hypersensitivity—Vinorelbine—ovarian cancer	0.00156	0.00317	CcSEcCtD
Plerixafor—Dermatitis—Topotecan—ovarian cancer	0.00156	0.00316	CcSEcCtD
Plerixafor—Headache—Topotecan—ovarian cancer	0.00155	0.00315	CcSEcCtD
Plerixafor—Vomiting—Melphalan—ovarian cancer	0.00154	0.00313	CcSEcCtD
Plerixafor—Immune system disorder—Docetaxel—ovarian cancer	0.00154	0.00311	CcSEcCtD
Plerixafor—Loss of consciousness—Paclitaxel—ovarian cancer	0.00154	0.00311	CcSEcCtD
Plerixafor—Rash—Melphalan—ovarian cancer	0.00153	0.0031	CcSEcCtD
Plerixafor—Dermatitis—Melphalan—ovarian cancer	0.00153	0.0031	CcSEcCtD
Plerixafor—Asthenia—Vinorelbine—ovarian cancer	0.00152	0.00308	CcSEcCtD
Plerixafor—Orthostatic hypotension—Epirubicin—ovarian cancer	0.00152	0.00307	CcSEcCtD
Plerixafor—Pruritus—Vinorelbine—ovarian cancer	0.0015	0.00304	CcSEcCtD
Plerixafor—Mental disorder—Docetaxel—ovarian cancer	0.00149	0.00302	CcSEcCtD
Plerixafor—Arthralgia—Paclitaxel—ovarian cancer	0.00149	0.00302	CcSEcCtD
Plerixafor—Erythema—Docetaxel—ovarian cancer	0.00148	0.003	CcSEcCtD
Plerixafor—CXCR4—Disease—CHMP4C—ovarian cancer	0.00148	0.0151	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.00148	0.00299	CcSEcCtD
Plerixafor—Nausea—Topotecan—ovarian cancer	0.00147	0.00298	CcSEcCtD
Plerixafor—Discomfort—Paclitaxel—ovarian cancer	0.00147	0.00298	CcSEcCtD
Plerixafor—Dry mouth—Paclitaxel—ovarian cancer	0.00146	0.00295	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—STAT3—ovarian cancer	0.00145	0.0148	CbGpPWpGaD
Plerixafor—Diarrhoea—Vinorelbine—ovarian cancer	0.00145	0.00294	CcSEcCtD
Plerixafor—Abdominal distension—Epirubicin—ovarian cancer	0.00145	0.00293	CcSEcCtD
Plerixafor—Nausea—Melphalan—ovarian cancer	0.00144	0.00292	CcSEcCtD
Plerixafor—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00143	0.00289	CcSEcCtD
Plerixafor—Shock—Paclitaxel—ovarian cancer	0.0014	0.00284	CcSEcCtD
Plerixafor—Dizziness—Vinorelbine—ovarian cancer	0.0014	0.00284	CcSEcCtD
Plerixafor—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.0014	0.00284	CcSEcCtD
Plerixafor—Nervous system disorder—Paclitaxel—ovarian cancer	0.0014	0.00283	CcSEcCtD
Plerixafor—Skin disorder—Paclitaxel—ovarian cancer	0.00139	0.00281	CcSEcCtD
Plerixafor—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00138	0.00279	CcSEcCtD
Plerixafor—Vomiting—Vinorelbine—ovarian cancer	0.00135	0.00273	CcSEcCtD
Plerixafor—Rash—Vinorelbine—ovarian cancer	0.00134	0.00271	CcSEcCtD
Plerixafor—Dermatitis—Vinorelbine—ovarian cancer	0.00134	0.00271	CcSEcCtD
Plerixafor—Abdominal distension—Doxorubicin—ovarian cancer	0.00134	0.00271	CcSEcCtD
Plerixafor—Headache—Vinorelbine—ovarian cancer	0.00133	0.00269	CcSEcCtD
Plerixafor—Syncope—Docetaxel—ovarian cancer	0.00133	0.00269	CcSEcCtD
Plerixafor—Loss of consciousness—Docetaxel—ovarian cancer	0.0013	0.00264	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.0013	0.00263	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HSD17B6—ovarian cancer	0.0013	0.0132	CbGpPWpGaD
Plerixafor—Insomnia—Paclitaxel—ovarian cancer	0.00129	0.00261	CcSEcCtD
Plerixafor—CXCR4—Disease—BCL9—ovarian cancer	0.00129	0.0131	CbGpPWpGaD
Plerixafor—Paraesthesia—Paclitaxel—ovarian cancer	0.00128	0.0026	CcSEcCtD
Plerixafor—Dyspnoea—Paclitaxel—ovarian cancer	0.00127	0.00258	CcSEcCtD
Plerixafor—Arthralgia—Docetaxel—ovarian cancer	0.00126	0.00256	CcSEcCtD
Plerixafor—Nausea—Vinorelbine—ovarian cancer	0.00126	0.00255	CcSEcCtD
Plerixafor—Dyspepsia—Paclitaxel—ovarian cancer	0.00126	0.00254	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00125	0.00254	CcSEcCtD
Plerixafor—Dry mouth—Docetaxel—ovarian cancer	0.00123	0.0025	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00123	0.0025	CcSEcCtD
Plerixafor—Fatigue—Paclitaxel—ovarian cancer	0.00123	0.00249	CcSEcCtD
Plerixafor—Pain—Paclitaxel—ovarian cancer	0.00122	0.00247	CcSEcCtD
Plerixafor—Constipation—Paclitaxel—ovarian cancer	0.00122	0.00247	CcSEcCtD
Plerixafor—Anaphylactic shock—Docetaxel—ovarian cancer	0.00121	0.00245	CcSEcCtD
Plerixafor—Shock—Docetaxel—ovarian cancer	0.00119	0.00241	CcSEcCtD
Plerixafor—Nervous system disorder—Docetaxel—ovarian cancer	0.00119	0.0024	CcSEcCtD
Plerixafor—Feeling abnormal—Paclitaxel—ovarian cancer	0.00118	0.00238	CcSEcCtD
Plerixafor—Skin disorder—Docetaxel—ovarian cancer	0.00118	0.00238	CcSEcCtD
Plerixafor—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.00117	0.00236	CcSEcCtD
Plerixafor—Haemoglobin—Epirubicin—ovarian cancer	0.00115	0.00234	CcSEcCtD
Plerixafor—Haemorrhage—Epirubicin—ovarian cancer	0.00115	0.00233	CcSEcCtD
Plerixafor—CXCR4—CXCR4-mediated signaling events—PIK3CA—ovarian cancer	0.00115	0.0117	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—AKT1—ovarian cancer	0.00114	0.0115	CbGpPWpGaD
Plerixafor—Urticaria—Paclitaxel—ovarian cancer	0.00113	0.0023	CcSEcCtD
Plerixafor—Connective tissue disorder—Epirubicin—ovarian cancer	0.00113	0.00229	CcSEcCtD
Plerixafor—Abdominal pain—Paclitaxel—ovarian cancer	0.00113	0.00229	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—DLC1—ovarian cancer	0.0011	0.0112	CbGpPWpGaD
Plerixafor—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.0011	0.00223	CcSEcCtD
Plerixafor—Insomnia—Docetaxel—ovarian cancer	0.00109	0.00222	CcSEcCtD
Plerixafor—Paraesthesia—Docetaxel—ovarian cancer	0.00109	0.0022	CcSEcCtD
Plerixafor—Dyspnoea—Docetaxel—ovarian cancer	0.00108	0.00218	CcSEcCtD
Plerixafor—Haemoglobin—Doxorubicin—ovarian cancer	0.00107	0.00216	CcSEcCtD
Plerixafor—Dyspepsia—Docetaxel—ovarian cancer	0.00107	0.00216	CcSEcCtD
Plerixafor—Haemorrhage—Doxorubicin—ovarian cancer	0.00106	0.00215	CcSEcCtD
Plerixafor—Hypersensitivity—Paclitaxel—ovarian cancer	0.00105	0.00213	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00104	0.00212	CcSEcCtD
Plerixafor—Connective tissue disorder—Doxorubicin—ovarian cancer	0.00104	0.00211	CcSEcCtD
Plerixafor—Fatigue—Docetaxel—ovarian cancer	0.00104	0.00211	CcSEcCtD
Plerixafor—Immune system disorder—Epirubicin—ovarian cancer	0.00104	0.0021	CcSEcCtD
Plerixafor—Constipation—Docetaxel—ovarian cancer	0.00103	0.0021	CcSEcCtD
Plerixafor—Pain—Docetaxel—ovarian cancer	0.00103	0.0021	CcSEcCtD
Plerixafor—Asthenia—Paclitaxel—ovarian cancer	0.00102	0.00207	CcSEcCtD
Plerixafor—Pruritus—Paclitaxel—ovarian cancer	0.00101	0.00205	CcSEcCtD
Plerixafor—Mental disorder—Epirubicin—ovarian cancer	0.00101	0.00204	CcSEcCtD
Plerixafor—Erythema—Epirubicin—ovarian cancer	0.001	0.00202	CcSEcCtD
Plerixafor—Feeling abnormal—Docetaxel—ovarian cancer	0.000997	0.00202	CcSEcCtD
Plerixafor—Gastrointestinal pain—Docetaxel—ovarian cancer	0.00099	0.002	CcSEcCtD
Plerixafor—Flatulence—Epirubicin—ovarian cancer	0.000986	0.002	CcSEcCtD
Plerixafor—Diarrhoea—Paclitaxel—ovarian cancer	0.000977	0.00198	CcSEcCtD
Plerixafor—Immune system disorder—Doxorubicin—ovarian cancer	0.00096	0.00194	CcSEcCtD
Plerixafor—Abdominal pain—Docetaxel—ovarian cancer	0.000957	0.00194	CcSEcCtD
Plerixafor—CXCR4—Disease—PPP1CC—ovarian cancer	0.000956	0.00971	CbGpPWpGaD
Plerixafor—Dizziness—Paclitaxel—ovarian cancer	0.000944	0.00191	CcSEcCtD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CXCL8—ovarian cancer	0.000941	0.00956	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—AKT1—ovarian cancer	0.000937	0.00952	CbGpPWpGaD
Plerixafor—Mental disorder—Doxorubicin—ovarian cancer	0.000931	0.00189	CcSEcCtD
Plerixafor—Ill-defined disorder—Epirubicin—ovarian cancer	0.000928	0.00188	CcSEcCtD
Plerixafor—Erythema—Doxorubicin—ovarian cancer	0.000926	0.00187	CcSEcCtD
Plerixafor—Flatulence—Doxorubicin—ovarian cancer	0.000912	0.00185	CcSEcCtD
Plerixafor—Vomiting—Paclitaxel—ovarian cancer	0.000908	0.00184	CcSEcCtD
Plerixafor—Malaise—Epirubicin—ovarian cancer	0.000902	0.00183	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—BCL9—ovarian cancer	0.0009	0.00915	CbGpPWpGaD
Plerixafor—Rash—Paclitaxel—ovarian cancer	0.0009	0.00182	CcSEcCtD
Plerixafor—Dermatitis—Paclitaxel—ovarian cancer	0.000899	0.00182	CcSEcCtD
Plerixafor—Syncope—Epirubicin—ovarian cancer	0.000897	0.00182	CcSEcCtD
Plerixafor—Headache—Paclitaxel—ovarian cancer	0.000895	0.00181	CcSEcCtD
Plerixafor—Hypersensitivity—Docetaxel—ovarian cancer	0.000892	0.00181	CcSEcCtD
Plerixafor—Loss of consciousness—Epirubicin—ovarian cancer	0.000879	0.00178	CcSEcCtD
Plerixafor—Asthenia—Docetaxel—ovarian cancer	0.000868	0.00176	CcSEcCtD
Plerixafor—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000859	0.00174	CcSEcCtD
Plerixafor—Pruritus—Docetaxel—ovarian cancer	0.000856	0.00173	CcSEcCtD
Plerixafor—Arthralgia—Epirubicin—ovarian cancer	0.000852	0.00172	CcSEcCtD
Plerixafor—Nausea—Paclitaxel—ovarian cancer	0.000848	0.00172	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000846	0.00171	CcSEcCtD
Plerixafor—Discomfort—Epirubicin—ovarian cancer	0.000841	0.0017	CcSEcCtD
Plerixafor—Malaise—Doxorubicin—ovarian cancer	0.000835	0.00169	CcSEcCtD
Plerixafor—Dry mouth—Epirubicin—ovarian cancer	0.000833	0.00169	CcSEcCtD
Plerixafor—Syncope—Doxorubicin—ovarian cancer	0.00083	0.00168	CcSEcCtD
Plerixafor—Diarrhoea—Docetaxel—ovarian cancer	0.000828	0.00168	CcSEcCtD
Plerixafor—Anaphylactic shock—Epirubicin—ovarian cancer	0.000816	0.00165	CcSEcCtD
Plerixafor—Loss of consciousness—Doxorubicin—ovarian cancer	0.000813	0.00165	CcSEcCtD
Plerixafor—Shock—Epirubicin—ovarian cancer	0.000803	0.00163	CcSEcCtD
Plerixafor—Nervous system disorder—Epirubicin—ovarian cancer	0.000801	0.00162	CcSEcCtD
Plerixafor—Dizziness—Docetaxel—ovarian cancer	0.0008	0.00162	CcSEcCtD
Plerixafor—CXCR4—G alpha (i) signalling events—CXCL8—ovarian cancer	0.000794	0.00807	CbGpPWpGaD
Plerixafor—Skin disorder—Epirubicin—ovarian cancer	0.000793	0.00161	CcSEcCtD
Plerixafor—Hyperhidrosis—Epirubicin—ovarian cancer	0.000789	0.0016	CcSEcCtD
Plerixafor—Arthralgia—Doxorubicin—ovarian cancer	0.000788	0.0016	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000783	0.00158	CcSEcCtD
Plerixafor—Discomfort—Doxorubicin—ovarian cancer	0.000778	0.00158	CcSEcCtD
Plerixafor—Dry mouth—Doxorubicin—ovarian cancer	0.000771	0.00156	CcSEcCtD
Plerixafor—Vomiting—Docetaxel—ovarian cancer	0.00077	0.00156	CcSEcCtD
Plerixafor—Rash—Docetaxel—ovarian cancer	0.000763	0.00154	CcSEcCtD
Plerixafor—Dermatitis—Docetaxel—ovarian cancer	0.000762	0.00154	CcSEcCtD
Plerixafor—Headache—Docetaxel—ovarian cancer	0.000758	0.00153	CcSEcCtD
Plerixafor—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000755	0.00153	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000744	0.00151	CcSEcCtD
Plerixafor—Shock—Doxorubicin—ovarian cancer	0.000743	0.0015	CcSEcCtD
Plerixafor—Nervous system disorder—Doxorubicin—ovarian cancer	0.000741	0.0015	CcSEcCtD
Plerixafor—Insomnia—Epirubicin—ovarian cancer	0.000738	0.00149	CcSEcCtD
Plerixafor—Skin disorder—Doxorubicin—ovarian cancer	0.000734	0.00149	CcSEcCtD
Plerixafor—Paraesthesia—Epirubicin—ovarian cancer	0.000733	0.00148	CcSEcCtD
Plerixafor—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00073	0.00148	CcSEcCtD
Plerixafor—Dyspnoea—Epirubicin—ovarian cancer	0.000728	0.00147	CcSEcCtD
Plerixafor—CXCR4—Disease—HDAC6—ovarian cancer	0.000724	0.00736	CbGpPWpGaD
Plerixafor—Nausea—Docetaxel—ovarian cancer	0.000719	0.00146	CcSEcCtD
Plerixafor—Dyspepsia—Epirubicin—ovarian cancer	0.000719	0.00145	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—DOK1—ovarian cancer	0.000712	0.00723	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000705	0.00143	CcSEcCtD
Plerixafor—Fatigue—Epirubicin—ovarian cancer	0.000704	0.00142	CcSEcCtD
Plerixafor—Constipation—Epirubicin—ovarian cancer	0.000698	0.00141	CcSEcCtD
Plerixafor—Pain—Epirubicin—ovarian cancer	0.000698	0.00141	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000688	0.00139	CcSEcCtD
Plerixafor—Insomnia—Doxorubicin—ovarian cancer	0.000683	0.00138	CcSEcCtD
Plerixafor—Paraesthesia—Doxorubicin—ovarian cancer	0.000678	0.00137	CcSEcCtD
Plerixafor—Dyspnoea—Doxorubicin—ovarian cancer	0.000673	0.00136	CcSEcCtD
Plerixafor—Feeling abnormal—Epirubicin—ovarian cancer	0.000673	0.00136	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—PPP1CC—ovarian cancer	0.000669	0.0068	CbGpPWpGaD
Plerixafor—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000668	0.00135	CcSEcCtD
Plerixafor—Dyspepsia—Doxorubicin—ovarian cancer	0.000665	0.00135	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000652	0.00132	CcSEcCtD
Plerixafor—Fatigue—Doxorubicin—ovarian cancer	0.000651	0.00132	CcSEcCtD
Plerixafor—Urticaria—Epirubicin—ovarian cancer	0.000649	0.00131	CcSEcCtD
Plerixafor—Constipation—Doxorubicin—ovarian cancer	0.000646	0.00131	CcSEcCtD
Plerixafor—Pain—Doxorubicin—ovarian cancer	0.000646	0.00131	CcSEcCtD
Plerixafor—Abdominal pain—Epirubicin—ovarian cancer	0.000645	0.00131	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	0.000631	0.00641	CbGpPWpGaD
Plerixafor—CXCR4—Disease—XIAP—ovarian cancer	0.000628	0.00638	CbGpPWpGaD
Plerixafor—Feeling abnormal—Doxorubicin—ovarian cancer	0.000622	0.00126	CcSEcCtD
Plerixafor—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000618	0.00125	CcSEcCtD
Plerixafor—CXCR4—Disease—SMARCA4—ovarian cancer	0.000612	0.00622	CbGpPWpGaD
Plerixafor—Hypersensitivity—Epirubicin—ovarian cancer	0.000601	0.00122	CcSEcCtD
Plerixafor—Urticaria—Doxorubicin—ovarian cancer	0.0006	0.00121	CcSEcCtD
Plerixafor—CXCR4—Disease—EREG—ovarian cancer	0.000597	0.00607	CbGpPWpGaD
Plerixafor—Abdominal pain—Doxorubicin—ovarian cancer	0.000597	0.00121	CcSEcCtD
Plerixafor—Asthenia—Epirubicin—ovarian cancer	0.000586	0.00119	CcSEcCtD
Plerixafor—Pruritus—Epirubicin—ovarian cancer	0.000578	0.00117	CcSEcCtD
Plerixafor—Diarrhoea—Epirubicin—ovarian cancer	0.000559	0.00113	CcSEcCtD
Plerixafor—Hypersensitivity—Doxorubicin—ovarian cancer	0.000557	0.00113	CcSEcCtD
Plerixafor—Asthenia—Doxorubicin—ovarian cancer	0.000542	0.0011	CcSEcCtD
Plerixafor—Dizziness—Epirubicin—ovarian cancer	0.00054	0.00109	CcSEcCtD
Plerixafor—Pruritus—Doxorubicin—ovarian cancer	0.000534	0.00108	CcSEcCtD
Plerixafor—CXCR4—Disease—FASN—ovarian cancer	0.000522	0.00531	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PARP1—ovarian cancer	0.00052	0.00529	CbGpPWpGaD
Plerixafor—Vomiting—Epirubicin—ovarian cancer	0.000519	0.00105	CcSEcCtD
Plerixafor—Diarrhoea—Doxorubicin—ovarian cancer	0.000517	0.00105	CcSEcCtD
Plerixafor—Rash—Epirubicin—ovarian cancer	0.000515	0.00104	CcSEcCtD
Plerixafor—Dermatitis—Epirubicin—ovarian cancer	0.000514	0.00104	CcSEcCtD
Plerixafor—Headache—Epirubicin—ovarian cancer	0.000511	0.00104	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HDAC6—ovarian cancer	0.000507	0.00515	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PPP2R1A—ovarian cancer	0.0005	0.00508	CbGpPWpGaD
Plerixafor—Dizziness—Doxorubicin—ovarian cancer	0.000499	0.00101	CcSEcCtD
Plerixafor—CXCR4—Disease—SLC2A1—ovarian cancer	0.000496	0.00504	CbGpPWpGaD
Plerixafor—Nausea—Epirubicin—ovarian cancer	0.000485	0.000982	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CXCL8—ovarian cancer	0.00048	0.00488	CbGpPWpGaD
Plerixafor—Vomiting—Doxorubicin—ovarian cancer	0.00048	0.000972	CcSEcCtD
Plerixafor—Rash—Doxorubicin—ovarian cancer	0.000476	0.000964	CcSEcCtD
Plerixafor—Dermatitis—Doxorubicin—ovarian cancer	0.000476	0.000963	CcSEcCtD
Plerixafor—Headache—Doxorubicin—ovarian cancer	0.000473	0.000958	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—YAP1—ovarian cancer	0.000449	0.00456	CbGpPWpGaD
Plerixafor—Nausea—Doxorubicin—ovarian cancer	0.000449	0.000908	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—XIAP—ovarian cancer	0.00044	0.00447	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—SMARCA4—ovarian cancer	0.000428	0.00436	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PPP2R1A—ovarian cancer	0.000422	0.00429	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EREG—ovarian cancer	0.000418	0.00425	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PGR—ovarian cancer	0.000392	0.00398	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CG—ovarian cancer	0.000369	0.00375	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PARP1—ovarian cancer	0.000364	0.0037	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6ST—ovarian cancer	0.000349	0.00354	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TERT—ovarian cancer	0.000335	0.00341	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CG—ovarian cancer	0.000335	0.0034	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CD—ovarian cancer	0.000324	0.00329	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CAV1—ovarian cancer	0.00031	0.00315	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PPP2R1A—ovarian cancer	0.000296	0.003	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CD—ovarian cancer	0.000294	0.00299	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6ST—ovarian cancer	0.000294	0.00299	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CB—ovarian cancer	0.000283	0.00287	CbGpPWpGaD
Plerixafor—CXCR4—Disease—APC—ovarian cancer	0.000282	0.00287	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—CXCL8—ovarian cancer	0.000272	0.00276	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—IL2—ovarian cancer	0.000259	0.00264	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CB—ovarian cancer	0.000257	0.00261	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CD—ovarian cancer	0.000248	0.00252	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—CXCL8—ovarian cancer	0.000247	0.00251	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL2—ovarian cancer	0.000236	0.0024	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TERT—ovarian cancer	0.000235	0.00239	CbGpPWpGaD
Plerixafor—CXCR4—Disease—ERBB2—ovarian cancer	0.000219	0.00223	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CAV1—ovarian cancer	0.000217	0.00221	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CB—ovarian cancer	0.000216	0.0022	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MTOR—ovarian cancer	0.000216	0.0022	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ESR1—ovarian cancer	0.000209	0.00213	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6ST—ovarian cancer	0.000206	0.00209	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CDKN1B—ovarian cancer	0.000203	0.00206	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—APC—ovarian cancer	0.000198	0.00201	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CG—ovarian cancer	0.000198	0.00201	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—NRAS—ovarian cancer	0.000198	0.00201	CbGpPWpGaD
Plerixafor—CXCR4—Disease—CTNNB1—ovarian cancer	0.000192	0.00195	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK3—ovarian cancer	0.000189	0.00193	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PTEN—ovarian cancer	0.000187	0.0019	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—MAPK1—ovarian cancer	0.00018	0.00183	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—EGFR—ovarian cancer	0.00018	0.00183	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CD—ovarian cancer	0.000174	0.00177	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—PIK3CA—ovarian cancer	0.000172	0.00175	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—KRAS—ovarian cancer	0.00017	0.00173	CbGpPWpGaD
Plerixafor—CXCR4—Disease—STAT3—ovarian cancer	0.000167	0.0017	CbGpPWpGaD
Plerixafor—CXCR4—Disease—NRAS—ovarian cancer	0.000167	0.0017	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK3—ovarian cancer	0.00016	0.00162	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—PIK3CA—ovarian cancer	0.000156	0.00159	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MYC—ovarian cancer	0.000155	0.00158	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—ERBB2—ovarian cancer	0.000154	0.00156	CbGpPWpGaD
Plerixafor—CXCR4—Disease—MAPK1—ovarian cancer	0.000152	0.00155	CbGpPWpGaD
Plerixafor—CXCR4—Disease—EGFR—ovarian cancer	0.000152	0.00155	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CB—ovarian cancer	0.000152	0.00154	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MTOR—ovarian cancer	0.000152	0.00154	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CXCL8—ovarian cancer	0.000146	0.00148	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—HRAS—ovarian cancer	0.000145	0.00147	CbGpPWpGaD
Plerixafor—CXCR4—Disease—KRAS—ovarian cancer	0.000144	0.00146	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CDKN1B—ovarian cancer	0.000142	0.00145	CbGpPWpGaD
Plerixafor—CXCR4—GPCR downstream signaling—AKT1—ovarian cancer	0.000141	0.00143	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CASP3—ovarian cancer	0.000139	0.00142	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL2—ovarian cancer	0.000139	0.00141	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—IL6—ovarian cancer	0.000139	0.00141	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCND1—ovarian cancer	0.000136	0.00138	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CTNNB1—ovarian cancer	0.000134	0.00137	CbGpPWpGaD
Plerixafor—CXCR4—Disease—PIK3CA—ovarian cancer	0.000132	0.00134	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—ovarian cancer	0.000132	0.00134	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PTEN—ovarian cancer	0.000131	0.00133	CbGpPWpGaD
Plerixafor—CXCR4—Signaling by GPCR—AKT1—ovarian cancer	0.000128	0.0013	CbGpPWpGaD
Plerixafor—CXCR4—Disease—HRAS—ovarian cancer	0.000122	0.00124	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—VEGFA—ovarian cancer	0.000118	0.0012	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—STAT3—ovarian cancer	0.000117	0.00119	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NRAS—ovarian cancer	0.000117	0.00119	CbGpPWpGaD
Plerixafor—CXCR4—Disease—IL6—ovarian cancer	0.000117	0.00119	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK3—ovarian cancer	0.000112	0.00114	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MYC—ovarian cancer	0.000109	0.00111	CbGpPWpGaD
Plerixafor—CXCR4—Disease—AKT1—ovarian cancer	0.000108	0.0011	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MAPK1—ovarian cancer	0.000106	0.00108	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—EGFR—ovarian cancer	0.000106	0.00108	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—KRAS—ovarian cancer	0.000101	0.00102	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—PIK3CA—ovarian cancer	9.24e-05	0.000939	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TP53—ovarian cancer	8.94e-05	0.000909	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—HRAS—ovarian cancer	8.55e-05	0.000869	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—IL6—ovarian cancer	8.18e-05	0.000832	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—AKT1—ovarian cancer	7.55e-05	0.000767	CbGpPWpGaD
